First author, year | Race | Pathologictype (E/C) | Sample size (E/C) | Specimen | lncRNA | State | Sen | Spe | TP | FP | FN | TN | QUADAS-2 | (Refs) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liu, 2019 | Asian | GC/HD | 89/73 | Serum | FEZF1-AS1 | Up | 75.3% | 65.8% | 67 | 25 | 22 | 48 | 5 | [15] |
 |  |  |  | AFAP1-AS1 | Up | 76.4% | 56.2% | 68 | 32 | 21 | 41 |  |  | |
Yoruke, 2018 | Caucasian | GC/non-GC | 40/42 | Plasma | H19 | Up | 87.2% | 38.1% | 35 | 26 | 5 | 16 | 6 | [16] |
Liu, 2019 | Asian | GC/HD | 100/100 | Serum | MALAT1 | Up | 85.8% | 74.5% | 86 | 26 | 14 | 75 | 4 | [17] |
Hashad, 2016 | Caucasian | GC/HD | 32/30 | Plasma | H19 | Up | 68.8% | 56.7% | 22 | 13 | 10 | 17 | 5 | [18] |
Li, 2014 | Asian | GC/HD | 79/81 | Plasma exosome | LINC00152 | Down | 48.1% | 85.2% | 38 | 12 | 41 | 69 | 6 | [19] |
Liu, 2014 | Asian | GC/HD | 83/80 | Plasma | FER1L4 | Up | 67.2% | 80.3% | 56 | 16 | 27 | 64 | 7 | [20] |
Liu, 2018 | Asian | GC/HD | 50/50 | Plasma | CTC-501O10.1 | Up | 90.0% | 51.0% | 45 | 25 | 5 | 26 | 6 | [21] |
 |  |  |  | AC100830.4 | Up | 84.0% | 58.0% | 42 | 21 | 8 | 29 |  |  | |
 |  |  |  | RP11-210K20.5 | Up | 89.0% | 55.0% | 45 | 23 | 6 | 28 |  |  | |
Lu, 2017 | Asian | EGC/HD | 76/76 | Serum | XIST | Up | 84.6% | 59.0% | 64 | 31 | 12 | 45 | 5 | [22] |
 |  |  |  | BCYRN1 | Up | 67.9% | 85.9% | 52 | 11 | 24 | 65 |  |  | |
 |  |  |  | RRP1B | Down | 85.9% | 56.4% | 65 | 33 | 11 | 43 |  |  | |
 |  |  |  | TDRG1 | Down | 73.1% | 60.3% | 56 | 30 | 20 | 46 |  |  | |
Mohamed, 2019 | Caucasian | GC/HD | 35/25 | Serum | H19 | Up | 90.9% | 100.0% | 32 | 0 | 3 | 25 | 5 | [23] |
Piao, 2020 | Asian | GC/HD | 281/80 | Plasma exosome | CEBPA-AS1 | Up | 74.0% | 88.0% | 208 | 10 | 73 | 70 | 6 | [24] |
Zhou, 2016 | Asian | GC/HD | 77/60 | Plasma | ZFAS1 | Up | 76.6% | 63.9% | 59 | 22 | 18 | 38 | 5 | [25] |
Cai, 2019 | Asian | GC/HD | 63/29 | Serum exosome | PCSK2-2:1 | Up | 84.0% | 86.5% | 53 | 4 | 10 | 25 | 6 | [26] |
Zhou, 2015 | Asian | GC/HD | 90/90 | Plasma | H19 | Up | 82.9% | 72.9% | 75 | 24 | 15 | 66 | 7 | [27] |
Elsayed, 2018 | Caucasian | GC/HD | 50/50 | Plasma | HOTAIR | Up | 86.0% | 94.0% | 43 | 3 | 7 | 47 | 4 | [28] |
Xian, 2018 | Asian | GC/HD | 50/50 | Plasma | HULC | Up | 58.0% | 80.0% | 29 | 10 | 21 | 40 | 5 | [29] |
 |  |  |  | ZNFX1-AS1 | Up | 84.0% | 68.0% | 42 | 16 | 8 | 34 |  |  | |
Feng, 2019 | Asian | GC/HD | 107/87 | Serum | B3GALT5-AS1 | Up | 64.5% | 87.4% | 69 | 11 | 38 | 76 | 5 | [30] |
Fu, 2017 | Asian | GC/HD | 72/72 | Serum | LINC00978 | Up | 80.0% | 70.0% | 58 | 22 | 14 | 50 | 5 | [31] |
Gao, 2015 | Asian | GC/HD | 20/20 | Plasma | UCA1 | Up | 85.0% | 96.3% | 17 | 1 | 3 | 19 | 6 | [32] |
 |  |  |  | PVT1 | Down | 70.8% | 91.3% | 14 | 2 | 6 | 18 |  |  | |
Ghaedi, 2018 | Asian | GC/HD | 62/40 | Plasma | H19 | Up | 74.2% | 90.0% | 46 | 4 | 16 | 36 | 6 | [33] |
 |  |  |  | MEG3 | Down | 77.4% | 52.5% | 48 | 19 | 14 | 21 |  |  | |
Guo, 2020 | Asian | EGC/HD | 217/219 | Plasma exosome | GC1 | Up | 97.0% | 83.0% | 210 | 37 | 7 | 182 | 5 | [34] |
Arita, 2013 | Asian | GC/HD | 43/34 | Plasma | H19 | Up | 74.0% | 58.0% | 32 | 14 | 11 | 20 | 6 | [35] |
Ji, 2019 | Asian | GC/HD | 168/74 | Plasma | LINC00086 | Down | 72.6% | 83.8% | 122 | 12 | 46 | 62 | 7 | [36] |
Jiang, 2019 | Asian | GC/HD | 317/100 | Plasma | PCGEM1 | Up | 72.9% | 88.9% | 231 | 11 | 86 | 89 | 7 | [7] |
Lin, 2018 | Asian | GC/HD | 51/60 | Plasma exosome | UEGC1 | Up | 88.0% | 82.0% | 45 | 11 | 6 | 49 | 5 | [37] |
 |  |  |  | UEGC2 | Up | 89.0% | 58.0% | 45 | 25 | 6 | 35 |  |  | |
Pan, 2017 | Asian | GC/HD | 60/37 | Serum exosome | ZFAS1 | Up | 71.7% | 75.7% | 43 | 9 | 17 | 28 | 5 | [38] |
Jin, 2016 | Asian | GC/HD | 173/110 | Serum | HULC | Up | 82.0% | 83.6% | 142 | 18 | 31 | 92 | 6 | [39] |
Zhang, 2018 | Asian | GC/HD | 57/29 | Serum exosome | UFC1 | Up | 78.0% | 80.0% | 44 | 6 | 13 | 23 | 5 | [2] |
Zhao, 2018 | Asian | GC/HD | 126/120 | Serum exosome | HOTTIP | Up | 69.8% | 85.0% | 88 | 18 | 38 | 102 | 4 | [40] |
Burock, 2015 | Caucasian | GC/non-GC | 76/54 | Plasma | MACC1 | Up | 68.0% | 89.0% | 52 | 6 | 24 | 48 | 5 | [41] |
Ke, 2017 | Asian | GC/HD | 51/53 | Plasma | INHBAAS1 | Down | 92.7% | 74.5% | 47 | 14 | 4 | 39 | 6 | [42] |
 |  |  |  | MIR4435-2HG | Down | 90.2% | 74.5% | 46 | 14 | 5 | 39 |  |  | |
 |  |  |  | CEBPA-AS1 | Down | 78.0% | 76.6% | 40 | 12 | 11 | 41 |  |  | |
 |  |  |  | UCA1 | Down | 73.2% | 82.3% | 37 | 9 | 14 | 44 |  |  | |
 |  |  |  | AK001058 | Down | 95.1% | 72.3% | 49 | 15 | 2 | 38 |  |  | |
 |  | 47/52 | Plasma | INHBAAS1 | Down | 82.7% | 59.6% | 39 | 21 | 8 | 31 |  |  | |
 |  |  |  | MIR4435-2HG | Down | 65.4% | 87.2% | 31 | 7 | 16 | 45 |  |  | |
 |  |  |  | CEBPA-AS1 | Down | 96.2% | 57.4% | 45 | 22 | 2 | 30 |  |  | |
 |  |  |  | AK001058 | Down | 76.9% | 92.3% | 36 | 4 | 11 | 48 |  |  | |
Liu, 2019 | Asian | GC/HD | 94/40 | Serum | HOXA11-AS | Up | 78.7% | 97.8% | 74 | 1 | 20 | 39 | 7 | [43] |
Shan, 2019 | Asian | GC/HD | 117/100 | Serum | UCA1 | Up | 93.2% | 78.6% | 109 | 21 | 8 | 79 | 6 | [44] |
Shao, 2016 | Asian | GC/HD | 83/90 | Plasma | RMRP | Down | 59.1% | 67.8% | 49 | 29 | 34 | 61 | 5 | [45] |
Yang, 2019 | Asian | GC/HD | 109/106 | Plasma | FOXD2-AS1 | Up | 83.0% | 50.0% | 90 | 53 | 19 | 53 | 5 | [46] |
 |  |  |  | PANDAR | Up | 85.0% | 63.0% | 93 | 39 | 16 | 67 |  |  | |
 |  |  |  | SMARCC2 | Up | 90.0% | 55.0% | 98 | 48 | 11 | 58 |  |  | |
Xu, 2020 | Asian | GC/HD | 109/50 | Serum | MIAT | Up | 81.5% | 87.5% | 89 | 6 | 20 | 44 | 5 | [47] |
Xu, 2018 | Asian | GC/HD | 34/34 | Plasma | DGCR5 | Down | 58.0% | 87.0% | 20 | 4 | 14 | 30 | 6 | [48] |
Xu, 2019 | Asian | GC/HD | 45/45 | Plasma | LINC01225 | Up | 50.0% | 90.0% | 23 | 5 | 23 | 41 | 4 | [49] |
Yang, 2016 | Asian | GC/HD+GS | 133/152 | Serum | H19 | Up | 65.0% | 53.0% | 86 | 71 | 47 | 81 | 7 | [50] |
 |  |  |  | LINC00152 | Up | 40.0% | 72.0% | 53 | 43 | 80 | 109 |  |  | |
Zheng, 2020 | Asian | GC/HD | 60/60 | Plasma | SLC2A12-10:1 | Up | 68.0% | 75.0% | 41 | 15 | 19 | 45 | 5 | [51] |
Zheng, 2018 | Asian | GC/HD | 241/228 | Plasma | FAM49B-AS | Up | 58.0% | 60.0% | 140 | 91 | 101 | 137 | 6 | [52] |
 |  |  |  | GUSBP11 | Up | 46.0% | 75.0% | 111 | 57 | 130 | 171 |  |  | |
 |  |  |  | CTDHUT | Up | 73.0% | 65.0% | 176 | 80 | 65 | 148 |  |  | |
Zhou, 2020 | Asian | GC/GS+GA+GD | 200/278 | Serum | C5orf66-AS1 | Down | 77.5% | 53.6% | 155 | 129 | 45 | 149 | 6 | [53] |
Tan, 2016 | Asian | GC/HD | 117/80 | Plasma | GACAT2 | Down | 87.2% | 28.2% | 102 | 57 | 15 | 23 | 5 | [54] |